New Korean Stem Cell Hub Coming to Baltimore, Focused on OA and Alzheimer’s Research
Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported by the Maryland Stem Cell Research Fund.
Korea’s Nature Cell plans to open a 100,000-square-foot stem cell manufacturing facility in Baltimore, expected to create 500 new jobs.
The site will be located at 1401 Severn Street within the Gaslight Square complex and is scheduled for completion in two phases by 2031.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The Baltimore facility will be operated by its subsidiary, Nature Cell America, and will focus on stem cell research related to knee osteoarthritis and Alzheimer’s disease, as well as clinical trials and manufacturing of its investigational products. The company reports it aims to produce up to one million doses per year of its stem cell injection product, JointStem, which received FDA Breakthrough Designation (BTD) earlier this year.
The company cited Maryland’s Stem Cell Research Fund (MSCRF) and available local skilled workforce as primary reasons for selecting Baltimore.
The Maryland Department of Commerce is working on a $4 million conditional loan toward project costs. The Baltimore Development Corporation plans an additional $400,000 conditional loan, along with assistance in expediting permitting processes.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell TherapyEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy Trial
Ernexa Therapeutics Reports Positive Preclinical iPSC-Derived Mesenchymal Stem Cell Study, Advances Oncology Strategy
